Claims

1. A STAT 6 activation inhibitor which comprises a diaminopyrimidinecarboxamide derivative represented by a formula (I) or a salt thereof and a pharmaceutically acceptable carrier,



(I)

(symbols in the formula have the following meanings:

A^1: CR^5 or N,

R^5: -H, -lower alkyl, -O-lower alkyl or -halogen,

A^2: CR^6 or N,

R^6: -H or -halogen,

R^3: $-R^0$, -lower alkyl substituted with halogen, -halogen, $-OR^0$, -S-lower alkyl, -CO-lower alkyl, $-CO_2$-lower alkyl, -lower alkylene-OH, -hetero ring, -O-hetero ring, $-N(R^0)$-hetero ring, -lower alkylene-hetero ring, -O-lower alkylene-hetero ring, -S-lower alkylene-hetero ring, -SO-lower alkylene-hetero ring, $-SO_2$-lower alkylene-hetero ring, $-N(R^0)$-lower alkylene-hetero ring, -lower alkylene-CO-hetero ring, -lower alkylene-$N(R^0)_2$, $-SO_2-N(R^0)$-lower alkyl or -lower alkylene-$N(R^0)-CO_2$-lower alkylene-phenyl,

R^0: the same or different from one another, and each is H or a lower alkyl,

n: 0 or 2,

R^4: (i) when n = 2, $-R^0$, -lower alkyl substituted with halogen, $-OR^0$, $-N(R^0)-CHO$, $-N(R^0)-CO$-lower alkyl or $-N(R^0)-SO_2$-lower alkyl,

(ii) when n = 0, -H, -lower alkyl substituted with halogen, -OH, -NH-CHO, $-CON(R^0)_2$, -lower alkylene substituted with halogen-OH, -lower alkylene-NH_2, -lower alkylene-$NHCONH_2$, -lower alkylene-CO_2H, -lower alkylene-CO_2-lower alkyl, -lower alkylene-CN, or $-CH(\text{lower alkylene-OH})_2$, or a group represented by a formula $-X^a-R^{4a}$,

X^a: single bond, -O-, -CO-, -S-, $-SO_2-$, $-N(R^0)-$, $-N(R^0)CO-$, $-N(R^0)SO_2-$, -lower alkylene-O-, -lower alkylene-$N(R^0)-$, -lower alkylene-$N(R^0)CO-$, -lower alkylene-$N(R^0)SO_2-$, -lower alkylene-$N(R^0)CO_2-$, $-N(CO-R^0)-$, $-N(SO_2\text{-lower alkyl})-$, $-CON(R^0)-$, -lower alkylene-O-CO-, -lower alkenylene-CO-, -lower alkenylene-$CON(R^0)-$, -lower alkenylene-CO_2-, $-O-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-N(R^0)-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-CO-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-CON(R^0)-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$ or $-N(R^0)CO-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$,

k and m, the same or different from each other, and each is 0, 1, 2, 3 or 4,

R^{4a}: lower alkyl, phenyl, hetero ring, cycloalkyl, lower alkylene-phenyl, lower alkylene-hetero ring, lower

alkylene-OH, lower alkenyl, lower alkenylene-phenyl or lower alkenylene-hetero ring,

wherein the hetero rings in R^3 and R^{4a} may be substituted with 1 to 5 of lower alkyl, halogen, $-OR^0$, -S-lower alkyl, -S(O)-lower alkyl, $-SO_2$-lower alkyl, lower alkylene-OR^0, $-N(R^0)_2$, $-CO_2R^0$, $-CON(R^0)_2$, -CN, -CHO, $-SO_2N(R^0)_2$, $-N(R^0)-SO_2$-lower alkyl, $-N(R^0)-CO-N(R^0)_2$, $-N(R^0)-CO_2$-lower alkyl, $-N(R^0)-CO_2$-cycloalkyl, -NH-C(=NH)-NH-lower alkyl, -NH-C(=N-CN)-NH-lower alkyl, hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-NH-C(=NN)-NH_2, -O-phenyl, -CO-phenyl, $-N(R^0)-CO$-lower alkyl, $-N(R^0)-CO$-lower alkylene-$N(R^0)_2$, -lower alkylene-$N(R^0)-CO$-lower alkylene-$N(R^0)_2$, $-CO-N(R^0)-$lower alkylene-$N(R^0)_2$, -CO-lower alkylene-$N(R^0)_2$, -CO-lower alkylene-CO_2R^0, -lower alkylene-$N(R^0)_2$, -lower alkylene-CO_2R^0, -lower alkylene-CO-$N(R^0)_2$, -lower alkylene-$N(R^0)-CO$-lower alkyl, -lower alkylene-$N(R^0)-CO_2$-lower alkyl, -lower alkylene-$N(R^0)-SO_2$-lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, $=N-O-R^0$ or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or $N(R^0)_2$, and

wherein the lower alkylene in R^3, R^4, R^{4a} and X^a may be substituted with 1 to 5 of $-OR^0$, $-CO_2R^0$, $-CON(R^0)_2$, $-N(R^0)_2$, $-N(R^0)COR^0$ or hetero ring, or

R^3 and R^4 may together form *$-N(R^7)-(CH_2)_2-$, *$-(CH_2)_2-N(R^7)-$, *$-CH_2-N(R^7)-CH_2-$, *$-N(R^7)-(CH_2)_3-$, *$-(CH_2)_3-N(R^7)-$, *$-CH_2-N(R^7)-(CH_2)_2-$, *$-(CH_2)_2-N(R^7)-CH_2-$, *$-C(O)-N(R^7)-(CH_2)_2-$, *$-(CH_2)_2-N(R^7)-C(O)-$, *$-N(R^7)-CH=CH-$, *$-CH=CH-N(R^7)-$, *$-N=CH-CH=CH-$, *$-CH=N-CH=CH-$, *$-CH=CH-N=CH-$, *$-CH=CH-CH=N-$, *$-N=CH-CH=N-$, *$-CH=N-N=CH-$, *$-N(R^7)-N=CH-$, *$-CH=N-N(R^7)-$, *$-O-CH_2-O-$, *$-O-(CH_2)_2-O-$, *$-O-(CH_2)_3-O-$, *$-O-(CH_2)_2-N(R^7)-$, *$-(CH_2)_2-C(O)-$, *$-CH=CH-C(O)-O-$ or *$-N=C(CF_3)-NH-$,

wherein * indicates bonding to the position shown by R^3,

R^7: -H, -lower alkyl or -CO-lower alkyl,

B: H, lower alkenyl, lower alkynyl, lower alkyl substituted with halogen, CN, S-lower alkyl, aryl which may have a substituent(s), cycloalkyl which may have a substituent(s) or hetero ring which may have a substituent(s),

Y: single bond; or lower alkylene which may be substituted with 1 to 5 groups selected from halogen, OH, O-lower alkyl, $-NH_2$, -NH-lower alkyl and $-N(\text{lower alkyl})_2$, and

R^1 and R^2: the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

2. The STAT 6 activation inhibitor described in claim 1, which is a Th2 cell differentiation inhibitor.

3. A diaminopyrimidinecarboxamide derivative represented by a formula (Ia) or a salt thereof,



(Ia)

(symbols in the formula have the following meanings:

A^1: CR^5 or N,

R^5: -H, -lower alkyl, -O-lower alkyl or -halogen,

R^3: $-R^0$, -lower alkyl substituted with halogen, -halogen, $-OR^0$, -S-lower alkyl, -CO-lower alkyl, $-CO_2$-lower alkyl, -lower alkylene-OH, -saturated hetero ring, $-X^b$-heteroaryl, $-X^b$-saturated hetero ring, $-X^b$-heteroaryl, -lower alkylene-$N(R^0)_2$, $-SO_2-N(R^0)$-lower alkyl or -lower alkylene-$N(R^0)-CO_2$-lower alkylene-phenyl,

X^b: -lower alkylene-, -O-lower alkylene-, -S-lower alkylene-, -SO-lower alkylene-, $-SO_2$-lower alkylene-, $-N(R^0)$-lower alkylene- or -lower alkylene-CO-,

R^0: the same or different from one another, and each represents H or a lower alkyl,

R^4: $-X^a$-saturated hetero ring, -lower alkylene-saturated hetero ring or -lower alkenylene-saturated hetero ring,

X^a: single bond, -O-, -CO-, -S-, $-SO_2$-, $-N(R^0)$-,

$-N(R^0)CO-$, $-N(R^0)SO_2-$, -lower alkylene-O-, -lower alkylene-$N(R^0)-$, -lower alkylene-$N(R^0)CO-$ or -lower alkylene-$N(R^0)SO_2-$, -lower alkylene-$N(R^0)CO_2-$, $-N(CO-R^0)-$, $-N(SO_2-$lower alkyl$)-$, $-CON(R^0)-$, -lower alkylene-O-CO-, -lower alkenylene-CO-, -lower alkenylene-$CON(R^0)-$, -lower alkenylene-CO_2-, $-O-(CH_2)_k-$cycloalkylene$-(CH_2)_m-$, $-N(R^0)-(CH_2)_k-$cycloalkylene$-(CH_2)_m-$, $-CO-(CH_2)_k-$cycloalkylene$-(CH_2)_m-$, $-CON(R^0)-(CH_2)_k-$cycloalkylene$-(CH_2)_m-$ or $-N(R^0)CO-(CH_2)_k-$cycloalkylene$-(CH_2)_m-$,

k and m: the same or different from each other, and each is 0, 1, 2, 3 or 4,

wherein the saturated hetero rings in R^3 and R^{4a} may be substituted with 1 to 5 of lower alkyl, halogen, $-OR^0$, -S-lower alkyl, -S(O)-lower alkyl, $-SO_2-$lower alkyl, lower alkylene-OR^0, $-N(R^0)_2$, $-CO_2R^0$, $-CON(R^0)_2$, -CN, -CHO, $-SO_2N(R^0)_2$, $-N(R^0)-SO_2-$lower alkyl, $-N(R^0)-CO-N(R^0)_2$, $-N(R^0)-CO_2-$lower alkyl, $-N(R^0)-CO_2-$cycloalkyl, -NH-C(=NH)-NH-lower alkyl, -NH-C(=N-CN)-NH-lower alkyl, saturated hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), heteroaryl, -lower alkylene-NH-C(=NN)-NH_2, -O-phenyl, -CO-phenyl, $-N(R^0)-$CO-lower alkyl, $-N(R^0)-$CO-lower alkylene-$N(R^0)_2$, -lower alkylene-$N(R^0)-$CO-lower alkylene-$N(R^0)_2$, -CO-$N(R^0)-$lower alkylene-$N(R^0)_2$, -CO-lower alkylene-$N(R^0)_2$, -CO-lower alkylene-CO_2R^0,

-lower alkylene-$N(R^0)_2$, -lower alkylene-CO_2R^0, -lower alkylene-CO-$N(R^0)_2$, -lower alkylene-$N(R^0)$-CO-lower alkyl, -lower alkylene-$N(R^0)$-CO_2-lower alkyl, -lower alkylene-$N(R^0)$-SO_2-lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, =N-O-R^0 or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or $N(R^0)_2$, and

wherein the lower alkylene in R^3, R^4 and X^a may be substituted with 1 to 5 of $-OR^0$, $-CO_2R^0$, $-CON(R^0)_2$, $-N(R^0)_2$, $-N(R^0)COR^0$ or hetero ring, or

R^3 and R^4 may together form *-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-, *-CH_2-$N(R^7)$-CH_2-, *-$N(R^7)$-$(CH_2)_3$-, *-$(CH_2)_3$-$N(R^7)$-, *-CH_2-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-CH_2-, *-$C(O)$-$N(R^7)$-$(CH_2)_2$-, *-$(CH_2)_2$-$N(R^7)$-$C(O)$-, *-$N(R^7)$-CH=CH-, *-CH=CH-$N(R^7)$-, *-N=CH-CH=CH-, *-CH=N-CH=CH-, *-CH=CH-N=CH-, *-CH=CH-CH=N-, *-N=CH-CH=N-, *-CH=N-N=CH-, *-$N(R^7)$-N=CH-, *-CH=N-$N(R^7)$-, *-O-CH_2-O-, *-O-$(CH_2)_2$-O-, *-O-$(CH_2)_3$-O-, *-O-$(CH_2)_2$-$N(R^7)$-, *-$(CH_2)_2$-$C(O)$-, *-CH=CH-$C(O)$-O- or *-N=$C(CF_3)$-NH-, wherein * indicates bonding to the position shown by R^3,

R^7: -H, -lower alkyl or -CO-lower alkyl,

B: aryl which may have a substituent(s) or heteroaryl which may have a substituent(s), and

R^1 and R^2: the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

4. A diaminopyrimidinecarboxamide derivative represented by a formula (Ib) or a salt thereof,



(Ib)

(symbols in the formula have the following meanings:

A^1: CR^5 or N,

R^5: -H, -lower alkyl, -O-lower alkyl or -halogen,

R^3: -saturated hetero ring or $-X^b$-saturated hetero ring,

X^b: -lower alkylene-, -O-, $-N(R^0)-$, -O-lower alkylene-, -S-lower alkylene-, -SO-lower alkylene-, $-SO_2$-lower alkylene-, $-N(R^0)$-lower alkylene- or -lower alkylene-CO-,

R^0: the same or different from one another, and each represents H or a lower alkyl,

R^4: -H, -lower alkyl substituted with halogen, -OH, -NH-CHO, $-CON(R^0)_2$, -lower alkylene substituted with halogen-OH, -lower alkylene-NH_2, -lower alkylene-$NHCONH_2$, -lower alkylene-CO_2H, -lower alkylene-CO_2-lower alkyl, -lower alkylene-CN, $-CH(\text{lower alkylene-OH})_2$ or $-X^a-R^{4a}$,

X^a: single bond, -O-, -CO-, -S-, $-SO_2-$, $-N(R^0)-$,

$-N(R^0)CO-$, $-N(R^0)SO_2-$, -lower alkylene-O-, -lower alkylene-$N(R^0)-$, -lower alkylene-$N(R^0)CO-$ or -lower alkylene-$N(R^0)SO_2-$, -lower alkylene-$N(R^0)CO_2-$, $-N(CO-R^0)-$, $-N(SO_2-$lower alkyl$)-$, $-CON(R^0)-$, -lower alkylene-O-CO-, -lower alkenylene-CO-, -lower alkenylene-$CON(R^0)-$, -lower alkenylene-CO_2-, $-O-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-N(R^0)-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-CO-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$, $-CON(R^0)-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$ or $-N(R^0)CO-(CH_2)_k$-cycloalkylene-$(CH_2)_m-$,

k and m: the same or different from each other, and each is 0, 1, 2, 3 or 4,

R^{4a}: lower alkyl, phenyl, heteroaryl, cycloalkyl, lower alkylene-phenyl, lower alkylene-heteroaryl, lower alkylene-OH, lower alkenyl, lower alkenylene-phenyl or lower alkenylene-heteroaryl,

wherein the saturated hetero ring and heteroaryl in R^3 and R^{4a} may be substituted with 1 to 5 of lower alkyl, halogen, $-OR^0$, -S-lower alkyl, -S(O)-lower alkyl, $-SO_2-$lower alkyl, lower alkylene-OR^0, $-N(R^0)_2$, $-CO_2R^0$, $-CON(R^0)_2$, -CN, -CHO, $-SO_2N(R^0)_2$, $-N(R^0)-SO_2-$lower alkyl, $-N(R^0)-CO-N(R^0)_2$, $-N(R^0)-CO_2-$lower alkyl, $-N(R^0)-CO_2-$cycloalkyl, -NH-C(=NH)-NH-lower alkyl, -NH-C(=N-CN)-NH-lower alkyl, hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-NH-C(=NN)-NH_2, -O-phenyl,

-CO-phenyl, -N(R^0)-CO-lower alkyl, -N(R^0)-CO-lower alkylene-N(R^0)$_2$, -lower alkylene-N(R^0)-CO-lower alkylene-N(R^0)$_2$, -CO-N(R^0)-lower alkylene-N(R^0)$_2$, -CO-lower alkylene-N(R^0)$_2$, -CO-lower alkylene-CO_2R^0, -lower alkylene-N(R^0)$_2$, -lower alkylene-CO_2R^0, -lower alkylene-CO-N(R^0)$_2$, -lower alkylene-N(R^0)-CO-lower alkyl, -lower alkylene-N(R^0)-CO_2-lower alkyl, -lower alkylene-N(R^0)-SO_2-lower alkyl, -lower alkylene-hetero ring (said hetero ring may be substituted with 1 to 5 substituents selected from lower alkyl, OH and lower alkylene-OH), -lower alkylene-O-lower alkylene-phenyl, =N-O-R^0 or oxo, and phenyl and cycloalkyl may be substituted with 1 to 5 of lower alkyl, OH, O-lower alkyl or N(R^0)$_2$, or

the lower alkylene in R^3, R^4, R^{4a} and X^a may be substituted with 1 to 5 of -OR^0, -CO_2R^0, -CON(R^0)$_2$, -N(R^0)$_2$, -N(R^0)COR^0 or hetero ring, or

R^3 and R^4 may together form *-N(R^7)-$(CH_2)_2$-, *-$(CH_2)_2$-N(R^7)-, *-CH_2-N(R^7)-CH_2-, *-N(R^7)-$(CH_2)_3$-, *-$(CH_2)_3$-N(R^7)-, *-CH_2-N(R^7)-$(CH_2)_2$-, *-$(CH_2)_2$-N(R^7)-CH_2-, *-C(O)-N(R^7)-$(CH_2)_2$-, *-$(CH_2)_2$-N(R^7)-C(O)-, *-N(R^7)-CH=CH-, *-CH=CH-N(R^7)-, *-N=CH-CH=CH-, *-CH=N-CH=CH-, *-CH=CH-N=CH-, *-CH=CH-CH=N-, *-N=CH-CH=N-, *-CH=N-N=CH-, *-N(R^7)-N=CH-, *-CH=N-N(R^7)-, *-O-CH_2-O-, *-O-$(CH_2)_2$-O-, *-O-$(CH_2)_3$-O-, *-O-$(CH_2)_2$-N(R^7)-, *-$(CH_2)_2$-C(O)-, *-CH=CH-C(O)-O- or *-N=C(CF_3)-NH-, wherein * indicates bonding to the position shown by R^3,

R^7: -H, -lower alkyl or -CO-lower alkyl,

B: aryl which may have a substituent(s) or heteroaryl which may have a substituent(s), and

R^1 and R^2: the same or different from each other, and each represents H, lower alkyl or O-lower alkyl which may have a substituent(s)).

5. A diaminopyrimidinecarboxamide derivative represented by a formula (Ic) or a salt thereof,



(Ic)

(symbols in the formula have the following meanings:

R^5: -H or -halogen,

B: phenyl which may have 1 to 3 substituents selected from lower alkyl and halogen,

Y: single bond or $-CH_2-$, and

R^1 and R^2: the same or different from each other, and each represents H or lower alkyl which may have a substituent(s)).

6. A diaminopyrimidinecarboxamide selected from the group consisting of 4-benzylamino-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 2-[(4-morpholin-4-ylphenyl)amino]-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-

5-carboxamide, 4-[(2,6-difluorobenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2,6-difluorobenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2-methoxybenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 4-[(2-fluoro-6-methoxybenzyl)amino]-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide, 2-({4-[(1-methylpiperidin-3-yl)oxy]phenyl}amino)-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)amino]-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-({4-[4-(2-amino-2-oxoethyl)piperazin-1-yl]phenyl}amino)-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(2-morpholin-4-ylethoxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 2-{[4-(β-D-glucopyranosyloxy)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide, 4-benzylamino-2-{[2-(3-chloro-4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide, 4-benzylamino-2-{[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino}pyrimidine-5-carboxamide, 2-[(4-morpholin-4-ylphenyl)amino]-4-[(2-thienylmethyl)amino]pyrimidine-5-carboxamide, 4-{[(3-

chloro-2-thienyl)methyl]amino}-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide and 2-{[3-(2-morpholin-4-ylethyl)phenyl]amino}-4-[(2,3,6-trifluorobenzyl)amino]pyrimidine-5-carboxamide or salts thereof.

7. A pharmaceutical composition which comprises the diaminopyrimidinecarboxamide derivative or a salt thereof described in claims 3 to 6 and a pharmaceutically acceptable carrier.

8. The composition described in claim 7, which is a preventive or therapeutic agent for respiratory diseases.

9. The composition described in claim 8, which is a preventive or therapeutic agent for asthma.

10. The composition described in claim 8, which is a preventive or therapeutic agent for a chronic obstructive pulmonary disease.

11. Use of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in claim 1, or a salt thereof, for the manufacture of an STAT 6 activation inhibitor.

12. Use of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in claim 1, or a salt thereof, for the manufacture of a Th2 cell differentiation inhibitor.

13. A method for inhibitory activity for STAT 6 activation, which comprises administering an effective amount of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in claim 1, or a salt thereof, to a mammal.

14. A method for inhibitory activity for Th2 cell differentiation, which comprises administering an effective amount of a diaminopyrimidinecarboxamide derivative represented by the general formula (I) described in claim 1, or a salt thereof, to a mammal.